SI
SI
discoversearch

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor.  We ask that you disable ad blocking while on Silicon Investor in the best interests of our community.  If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.
Biotech / Medical : Indications -- HIV
 Public ReplyPrvt ReplyMark as Last ReadFilePrevious 10Next 10PreviousNext  
To: tuck who wrote (129)4/11/2010 2:28:16 AM
From: idos  Read Replies (1) of 155
 
I remember Bristol-Myers-Squibb has a CCR2/CCR5 dual antagonist in preclinic study but think it is for cardiovascular indication. I see that Pfizer (they brought Selzentry to the market and has a 2nd generation oral CCR5 antagonist in the clinic), has such a compound in phase I but don't know to which indication could be HIV as well:

clinicaltrials.gov
Report TOU ViolationShare This Post
 Public ReplyPrvt ReplyMark as Last ReadFilePrevious 10Next 10PreviousNext  

HomeMailHotSubjectMarksPeopleMarksKeepersSettings
Terms Of UseContact UsCopyright/IP PolicyPrivacy PolicyAbout UsFAQAdvertise on SI
© 2025 Knight Sac Media.  Data provided by Twelve Data, Alpha Vantage, and CityFALCON News